Axela Bio, a CRO specializing in discovery biology and Translational Sciences.

Axela Bio, a CRO specializing in discovery biology and Translational Sciences.


A trusted New Jersey CRO, specializing in discovery biology, translational development, bioanalysis and CLIA testing to ACCELERATE the development of novel therapeutics and diagnostics.
Merged from PicoImmune, NanoBiotec and Emerther USA, offering highly sensitive, multiplex and reliable bioassays for real-time monitoring of protein and gene changes in minute samples.
Driving forward high-caliber innovations into therapeutics by maximizing insights from minute samples, delivering efficiency to our partner and benefit our patients today, rather tomorrow.


Our Vision
Axela Biosciences, Inc. offers highly sensitive, multiplex and reliable bioassay services for real-time monitoring of protein and gene changes in minute samples from cells, animals, and patients, thereby expediting the discovery and development of novel therapeutics.
Our Team
Our team possesses extensive expertise in drug discovery and unparalleled proficiency in bioanalytical, cytometric, genomic, and proteomic techniques. We harness the power of ultra-sensitive pico-scale and multiplex immunoassay as well as microarray technologies. Our employees have received training at prestigious institutions such as MIT, NIH, MSKCC, Rutgers, NYU, Duke and have accumulated decades of experience working for multinational biopharma companies including Novartis, Sanofi, Merck, BMS/Celgene, and Regeneron. We acquire and analyze data from multi-level experiments to assess drug efficacy while elucidating the underlying mechanisms of drugs and diseases.
Partnering
Axela Bio is a privately held contract research organization (CRO) committed to enhancing the efficiency of discovering innovative therapeutic drugs. We offer cost-effective services to biopharma and academic investigators, aiming to expedite the development of novel drugs and personalized medicine for cancer, autoimmune, and various other unmet medical conditions. Our strategic focus lies in establishing R&D partnerships with biotech, pharma, diagnostic companies, as well as academic institutions. Axela Bio welcomes proposals for R&D collaboration and strategic partnerships. For further information, please contact us at info@axelabio.com.
Our Platforms
We have established a state-of-the-art infrastructure equipped with cutting-edge technologies and advanced instruments. Our suite of sophisticated platforms enables highly sensitive bioanalysis and drug screening using minimal sample sizes, thereby allowing us to meet diverse assay performance requirements. Our dedicated scientists possess extensive hands-on experience and training in utilizing these technologies and instruments, diligently adhering to well-validated protocols for swift and accurate processing and analysis of samples.
WHY WORK WITH US?



















“...we very much appreciate your flexibility to work with us and allowed quick assessment of antibodies that might be useful for feasibility testing in… I also want to express our appreciation for your timely data communication, it was neat, clear, and transparent. Thank you for your partnership.”
--- BMS Principal Investigator, Cardiovascular Biology
“Working with Axela removes the guess work. I always know the status of my immune cell functional assay project because their team of scientists communicates regularly.”
---Senior Scientist, Gilead
